Establishment of Tumor-on-Chip system and TME cancer progression

Traditional cancer research has largely focused on 2D cell cultures, primarily investigating cancer epithelial cells and their genetics. However, the role of the tumor stroma and its microenvironment in cancer progression has gained significant attention. Despite advances, traditional preclinical models still struggle to mimic human physiology accurately. Recent innovations, like engineered co-culture systems and microfluidic organ-on-chip models, address these limitations by better simulating cell interactions and organ-level structures. Champions Oncology has developed the Tumor-on-Chip (TOC) platform, which integrates TumorGraft3D (CTG3D) biobank models, enabling more precise studies of tumor-immune interactions, particularly immune cell recruitment and the effects of the microenvironment on cancer therapy.

Traditional 2D models have limitations in replicating tumor microenvironments, prompting the development of more advanced co-culture systems.
Champions Oncology's Tumor-on-Chip (TOC) platform uses TumorGraft3D (CTG3D) models to study tumor-immune interactions, such as tumor-infiltrating lymphocyte (TIL) migration.
The TOC platform offers a robust, reproducible system for studying epithelial barrier integrity, immune responses, and testing immunotherapies.

Download Champions' SITC 2023 Poster

Establishment of Tumor-on-Chip system to study the role of tumor microenvironment on cancer progression in a patient-specific manner